Our method was shown to be feasible and safe. The success of the intralesional injection of the sclerosing agent may be predicted when changes in the mucosal surface are observed: (a) immediately after the injection sufficient sclerosant is deemed to have been injected and to the proper depth in the bowel wall, if the mucosa bulges while the solution is being injected; and (b) if a shallow ulceration is seen in an early subsequent reexamination where the treated lesion was located, allowing scar tissue produced by the healing process of the ulcer to replace the former vascular lesion.